Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid valued at around $469M. Read more here.

SAN FRANCISCO (Reuters) - Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO ...

Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own. The bid of $7.22 per share was a 30% premium to ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

On Friday, Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics ...

Biogen Inc. (NASDAQ:BIIB), a prominent biopharmaceutical company specializing in neurology and rare diseases with a market capitalization of $21.84 billion, finds itself at a critical juncture as ...